Latest news with #ServierGroup
United News of India
3 days ago
- Health
- United News of India
Servier India launches ‘Ivosidenib' Tibsovo
Kochi, Jun 10 (UNI) Servier India, a subsidiary of the leading French pharmaceutical Servier Group, has announced the launch of Ivosidenib (Tibsovo®), an oral targeted therapy approved in the management of cancer patients with Acute Myeloid Leukemia (AML) and Cholangiocarcinoma, with an isocitrate dehydrogenase-1 (IDH1) mutation. Servier India received the approval on 14th May 2025, from Central Drugs Standard Control Organisation (CDSCO) for the import, sale, and distribution of the medication. Acute myeloid leukemia is a challenging hematological malignancy. Studies indicate that only about 30–40 percent of AML patients in India receive adequate treatment, with high mortality rates due to rapid disease progression and infections. Cholangiocarcinomas (CCA) are rare tumours originating from the bile duct. Due to their asymptomatic nature, they are usually diagnosed when the disease is advanced. The announcement marks a significant advancement in the management of the mentioned rare and difficult-to-treat cancers in India, addressing a critical unmet medical need. Aurélien Breton, Managing Director, Servier India, said, 'Our focus is to advance oncology care by bringing innovative, precision medicines to patients who need them the most." "By prioritizing access and working to make treatment options affordable to patients, we are dedicated to bridging critical gaps in cancer care across the country. This launch will support healthcare providers with targeted treatment options and ultimately improve survival outcomes and quality of life for patients throughout India.' IDH1 mutation occurs in approximately 7–14 percent of AML patients in India, making targeted mechanisms especially relevant for this subset. 'This therapy represents a significant therapeutic option in the treatment of AML and Cholangiocarcinoma. For healthcare professionals, this precision therapy offers a new, effective option that can improve patient outcomes where traditional treatments have limited success. It highlights the benefits of targeted therapy and caliber of innovation in enhancing lives and advancing cancer care in India.', highlighted Dr. Pranav Sopory, Medical and Patient Affairs Director, Servier India. By introducing these advanced therapies, Servier India reaffirms its commitment to advancing innovative cancer treatments that improve clinical outcomes and enhance the quality of life of patient. UNI DS BD
Business Standard
05-06-2025
- Health
- Business Standard
Servier India introduces 'Ivosidenib'(Tibsovo®), in India, First-in-class Targeted Therapy in Oncology for Rare IDH1-Mutated AML and Cholangiocarcinoma
VMPL Mumbai (Maharashtra) [India], June 5: Servier India, a subsidiary of the leading French pharmaceutical Servier Group, today announced the launch of Ivosidenib (Tibsovo®), an oral targeted therapy approved in the management of cancer patients with Acute Myeloid Leukemia (AML) and Cholangiocarcinoma, with an isocitrate dehydrogenase-1 (IDH1) mutation. Servier India received the approval on 14th May 2025, from Central Drugs Standard Control Organisation (CDSCO) for the import, sale, and distribution of the medication. Acute myeloid leukemia is a challenging hematological malignancy. Studies indicate that only about 30-40% of AML patients in India receive adequate treatment1, with high mortality rates due to rapid disease progression and infections. Cholangiocarcinomas (CCA) are rare tumours originating from bile duct. Due to their asymptomatic nature they are usually diagnosed when the disease is advanced.2 The announcement marks a significant advancement in management of the mentioned rare and difficult-to-treat cancers in India, addressing a critical unmet medical need. Speaking on the occasion, Mr. Aurelien Breton, Managing Director, Servier India, said, "Our focus is to advance oncology care by bringing innovative, precision medicines to patients who need them the most. By prioritizing access and working to make treatment options affordable to patients, we are dedicated to bridging critical gaps in cancer care across the country. This launch is a significant step forward in our mission to support healthcare providers with targeted treatment options and ultimately improve survival outcomes and quality of life for patients throughout India." IDH1 mutation occurs in approximately 7-14% of AML patients in India3, making targeted mechanisms especially relevant for this subset. "This therapy represents a significant therapeutic option in the treatment of AML and Cholangiocarcinoma. For healthcare professionals, this precision therapy offers a new, effective option that can improve patient outcomes where traditional treatments have limited success. It highlights the benefits of targeted therapy and caliber of innovation in enhancing lives and advancing cancer care in India.", highlighted Dr. Pranav Sopory, Medical and Patient Affairs Director, Servier India. Speaking on the importance of treatment access, Ms. Pratima Tripathi, Commercial Director, Servier India, said: "Our foremost priority is to ensure that the therapy is accessible and affordable to patients across India. We are actively collaborating with healthcare providers, patient advocacy groups, and policymakers to remove barriers and facilitate timely access to this important therapy. Through these partnerships, we are committed to expanding treatment options and making a meaningful difference in the lives of patients." By introducing these advanced therapies, Servier India reaffirms its commitment to advancing innovative cancer treatments that improve clinical outcomes and enhance the quality of life of patients. Disclaimer: This press release is intended solely to share regulatory and medical information regarding the launch; the reference to "Tibsovo" is not intended as a promotional or public advertisement. Use of the therapy is strictly based on a doctor's prescription and clinical discretion. About Servier India Servier India has been committed for over three decades to delivering innovative pharmaceutical solutions that improve the lives of patients and their families across India. Established in 1985 as an affiliate of the leading independent French pharmaceutical Servier Group, the company focuses on therapeutic areas such as Cardiometabolism, Neuroscience, Venous Diseases, and Oncology. Servier India has a strong pan-India presence and a dedicated workforce of around 580 that strives to address critical healthcare challenges with passion and purpose. As part of Servier group operating in over 150 countries, Servier India inherits a rich legacy of scientific excellence and patient-centric innovation. Globally, Servier invests heavily in research and development, focusing on our key therapeutic areas. About Servier Servier is a global pharmaceutical group governed by a Foundation that aspires to serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. As a world leader in cardiometabolism and venous diseases, Servier's ambition is to become a focused and innovative player in oncology by targeting rare cancers. Headquartered in France, Servier relies on a strong geographical footprint; its medicines are available in close to 140 group achieved a revenue of EUR5.9 billion in 2024. Additional Details on Ivosidenib Internationally, Ivosidenib has already received regulatory approvals in more than 42 countries, including the USA, Europe, China, UAE, and South Korea. In the United States, the US FDA approved it in 2019 as a monotherapy and later in May 2022 as a combination treatment with Azacitidine for patients aged 75 and above, or those who cannot tolerate intensive chemotherapy. The European Medical Agency (EMA) gave its approval in May 2023 for use in patients who are not fit for standard induction chemotherapy. In India, the process moved forward in April 2025, when the Subject Expert Committee (SEC) gave a positive recommendation for Ivosidenib. Following this, the DCGI granted approval for the marketing authorization in May 2025
Zawya
10-02-2025
- Health
- Zawya
Servier Egypt celebrates jubilee with new production line, cancer programme
Egypt - Servier Egypt, part of the global Servier Group, has commemorated its 70th anniversary with the opening of a new production line and the launch of the 'Access Cancer Treatment (ACT) for Children' initiative. The announcements were made at an event attended by Ali El Ghamrawy, Head of the Egyptian Drug Authority, and Hesham Stait, Head of the Egyptian Authority for Unified Procurement. Stait highlighted the importance of public-private partnerships for Egypt's Vision 2030. Servier Egypt has been operating in the country for over 50 years, focusing on sustainable development and access to treatments. It currently produces 25 million boxes of medication annually for Egyptian patients. The company's pharmaceutical site in 6th of October City, one of Servier Group's eight worldwide, was established in 1994. Production has grown to 25 million boxes annually, with 90% for the local market and 10% exported to nine countries in Africa and the Middle East. Servier has invested over EGP 1.6 billion in its Egyptian operations, including EGP 370 million in 11 projects focused on capacity building, corporate social responsibility, and digital procedures. These include solar panels, a wastewater treatment system, and a new packaging line. The company aims to produce 50 million boxes annually by 2030, increasing exports and partnerships to position Egypt as a regional pharmaceutical hub. 'This milestone reaffirms our long-standing commitment to Egypt's Vision 2030,' said Samy Sinnuqrut, General Manager of Servier Egypt. 'By investing in local production and innovation, we aim to enhance patient access to advanced treatments while contributing to Egypt's economic and healthcare priorities.' Servier Egypt offers 34 medicines, including treatments for cardio-metabolism, venous diseases, and oncology, with plans to introduce two more oncology treatments. The ACT for Children initiative, in partnership with other organisations, addresses childhood cancer disparities. 'Through ACT for Children, we aim to create long-term infrastructure and sustainable healthcare solutions that ensure children everywhere have access to the care and treatments they need,' Sinnuqrut said. 'This is central to our Servier 2030 ambition to make a measurable, positive social impact.' Servier Egypt offers 32 solid dosage form products, along with two specialised oncology medications. © 2024 Daily News Egypt. Provided by SyndiGate Media Inc. (
Daily News Egypt
10-02-2025
- Health
- Daily News Egypt
Servier Egypt celebrates jubilee with new production line, cancer programme
Servier Egypt, part of the global Servier Group, has commemorated its 70th anniversary with the opening of a new production line and the launch of the 'Access Cancer Treatment (ACT) for Children' initiative. The announcements were made at an event attended by Ali El Ghamrawy, Head of the Egyptian Drug Authority, and Hesham Stait, Head of the Egyptian Authority for Unified Procurement. Stait highlighted the importance of public-private partnerships for Egypt's Vision 2030. Servier Egypt has been operating in the country for over 50 years, focusing on sustainable development and access to treatments. It currently produces 25 million boxes of medication annually for Egyptian patients. The company's pharmaceutical site in 6th of October City, one of Servier Group's eight worldwide, was established in 1994. Production has grown to 25 million boxes annually, with 90% for the local market and 10% exported to nine countries in Africa and the Middle East. Servier has invested over EGP 1.6 billion in its Egyptian operations, including EGP 370 million in 11 projects focused on capacity building, corporate social responsibility, and digital procedures. These include solar panels, a wastewater treatment system, and a new packaging line. The company aims to produce 50 million boxes annually by 2030, increasing exports and partnerships to position Egypt as a regional pharmaceutical hub. 'This milestone reaffirms our long-standing commitment to Egypt's Vision 2030,' said Samy Sinnuqrut, General Manager of Servier Egypt. 'By investing in local production and innovation, we aim to enhance patient access to advanced treatments while contributing to Egypt's economic and healthcare priorities.' Servier Egypt offers 34 medicines, including treatments for cardio-metabolism, venous diseases, and oncology, with plans to introduce two more oncology treatments. The ACT for Children initiative, in partnership with other organisations, addresses childhood cancer disparities. 'Through ACT for Children, we aim to create long-term infrastructure and sustainable healthcare solutions that ensure children everywhere have access to the care and treatments they need,' Sinnuqrut said. 'This is central to our Servier 2030 ambition to make a measurable, positive social impact.' Servier Egypt offers 32 solid dosage form products, along with two specialised oncology medications.
Zawya
06-02-2025
- Business
- Zawya
Servier Egypt celebrates Platinum Jubilee with expansion of state-of-the-art production line
Giza, Egypt: Servier Egypt, a leading player in the pharmaceutical industry and part of the global Servier Group, proudly marked its Platinum Jubilee in Egypt with the inauguration of an additional state-of-the-art production line and the launch of a groundbreaking health access program, "Access Cancer Treatment (ACT) for Children." These milestones coincide with the celebration of 70 years of Servier's global legacy. The event was graced by prominent dignitaries, including Dr. Ali El Ghamrawy, Head of the Egyptian Drug Authority, Dr. Hesham Stait, Head of the Egyptian Authority for Unified Procurement. In his remarks, he highlighted the importance of public-private partnerships in achieving Egypt's Vision 2030, particularly in areas like localized production, increased exports, and innovative healthcare solutions. For over five decades, Servier Egypt has been a trusted partner in the nation's healthcare journey, contributing to Egypt's Vision 2030 by prioritizing sustainable development, innovation, and expanding access to life-saving treatments. Today, Servier Egypt produces 25 million boxes for Egyptian patients annually. Servier Egypt's pharmaceutical site, with its two manufacturing facilities located in 6th of October, is one of eight Servier Group pharmaceutical sites worldwide. It was established in 1994 with an initial capacity to produce 5 million boxes annually. Today, the site is celebrating 30 years of serving patients with the highest product quality and safety standards. Volumes have grown year-over-year, reaching 25 million boxes, of which 90% is dedicated to the local market and 10% is exported to nine countries across Africa and the Middle East. In total, Servier has invested more than EGP 1.6 billion in its operations and production capacity in Egypt, of which EGP 370 million are being invested into a specific program, spanning 11 key projects focusing on capacity building, CSR, quality, safety and digital procedures. Extensive parts of this local-talent-led transformation have already been realized, including the installation of solar panels, a wastewater treatment system and a new high-speed packaging line. At the end of the transformation program, the site will mark a significant 2030 milestone of producing 50 million boxes annually. While continuing to meet local healthcare needs, this capacity will open the door to increase Servier Egypt's exports in the region and external partners. These steps perfectly reflect Servier's ambition to position Egypt as a regional hub for high-quality pharmaceutical manufacturing and export excellence. Samy Sinnuqrut, General Manager of Servier Egypt, stated, 'This milestone reaffirms our long-standing commitment to Egypt's Vision 2030. By investing in local production and innovation, we aim to enhance patient access to advanced treatments while contributing to Egypt's economic and healthcare priorities. Our goal is to provide cutting-edge medicines not only to Egypt but also to the wider region.' Servier Egypt offers a diverse portfolio of 34 medicines, addressing a wide range of therapeutic areas to meet the evolving needs of Egyptian patients. The company is a leader in cardio-metabolism and venous diseases (CMVD), providing innovative solutions for hypertension, diabetes, and heart failure. Additionally, Servier has made significant strides in oncology, bringing life-changing treatments for metastatic colorectal cancer and pancreatic cancer to EGYPT—two areas where medical needs are urgent. Our mission does not stop here. We are actively working to bring two more state-of-the-art oncology treatments to Egypt Servier also announced the debut of Access Cancer Treatment (ACT) for Children Initiative, a flagship health access program addressing childhood cancer disparities, in partnership with several organizations. The ACT for Children initiative focuses on providing access to quality medical care, empowering healthcare professionals with advanced skills, and expanding availability of life-saving treatments. 'Through ACT for Children, we aim to create long-term infrastructure and sustainable healthcare solutions that ensure children everywhere have access to the care and treatments they need,' added Sinnuqrut. 'This is central to our Servier 2030 ambition to make a measurable, positive social impact.' About Servier Egypt Servier Egypt is a leading pharmaceutical company with a strong presence in Egypt and a commitment to improving patient health. They offer a comprehensive portfolio of 32 solid dosage form products, along with 2 specialized oncology medications. This diverse range of medicines addresses various therapeutic areas and meets the evolving healthcare needs of Egyptians. For more information, please contact: Asmaa Ghoneim
